Hyaluronidase

Generic Name: Hyaluronidase

Brand Names: Amphadase

Drug Type: Biotech

CAS Number: 9001-54-1

Unique Ingredient Identifier: 8KOG53Z5EM

Background: Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents. The action of hyaluronidase was first described in 1936, and named in 1939. Early research into hyaluronidase identified it as a "spreading factor" which allowed for increased permeability of the connective tissue. Hyaluronidase has been used in surgical settings for at least the past 60 years to improve the diffusion of local anesthetics.

Hyaluronidase was first used in prescription products in the United States on 5 May 2004.

Indication: Hyaluronidase is indicated for subcutaneous fluid administration for hydration, and increasing resorption of radiopaque agents in subcutaneous urography. Hyaluronidase is also indicated by multiple routes to increase the dispersion of other injectable drugs.

Associated Therapies: Parenteral rehydration therapy, Parenteral drug administration, Subcutaneous urography

Clinical Trials

Ultrasound Guided Erector Spinae Plane Block in Breast Surgery

Not Applicable

Conditions: Postoperative Pain

Interventions: Drug: Local anesthetic
Drug: Hyaluronidase

First Posted Date: 2018-09-06

Last Posted Date: 2020-04-09

Lead Sponsor: Assiut University

Target Recruit Count: 60

Registration Number: NCT03660020

Locations: 🇪🇬
Assiut university, Assiut, Egypt

A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer

Early Phase 1

Terminated

Conditions: Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma

Interventions: Drug: PEGylated Recombinant Human Hyaluronidase (PEGPH20)
Drug: Avelumab

First Posted Date: 2018-03-29

Last Posted Date: 2019-08-22

Lead Sponsor: PH Research, S.L.

Target Recruit Count: 7

Registration Number: NCT03481920

Locations: 🇪🇸
Hospital Universitario La Paz, Madrid, Spain
🇪🇸
Hospital Universitario Fuenlabrada, Fuenlabrada, Madrid, Spain
🇪🇸
Hospital Ramon y Cajal, Madrid, Spain

Nalbuphine as an Adjuvant to Local Anaesthetic Mixture in Peribulbar Cataract Surgery

Not Applicable

Completed

Conditions: Nalbuphine as an Adjuvant to L. A in Peribulbar Block for Cataract Surgery

Interventions: Drug: lidocaine, bupivacaine, hyaluronidase , saline
Drug: Nalbuphine
Drug: lidocaine, bupivacaine , hyaluronidase

First Posted Date: 2018-02-19

Last Posted Date: 2018-05-30

Lead Sponsor: Cairo University

Target Recruit Count: 40

Registration Number: NCT03436836

Locations: 🇪🇬
Ahmed Abdalla Mohamed, Cairo, Egypt
🇪🇬
Ahmed Abdalla, Cairo, Egypt

Safety and Efficacy of Addition of Hyaluronidase to Lidocaine and Bupivacaine in Scalp Nerves Block in Elective Craniotomy Operations, Comparative Study

Early Phase 1

Completed

Conditions: Addition of Hyalase to Local Anesthetic in Scalp Block

Interventions: Drug: Hyaluronidase
Drug: Lidocaine
Drug: Bupivacaine

First Posted Date: 2018-01-26

Last Posted Date: 2018-04-27

Lead Sponsor: Cairo University

Target Recruit Count: 64

Registration Number: NCT03411330

Locations: 🇪🇬
Ahmed Abdalla Mohamed, Cairo, Egypt

Peripheral Modulation of Muscle Stiffness and Spasticity

Phase 2

Recruiting

Conditions: Muscle Spasticity

Interventions: Drug: Placebo
Drug: Hyaluronidase

First Posted Date: 2017-10-11

Last Posted Date: 2025-04-09

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 56

Registration Number: NCT03306615

Locations: 🇺🇸
Johns Hopkins School of Medicine, Baltimore, Maryland, United States

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Phase 1

Active, not recruiting

Conditions: Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma

Interventions: Drug: 5-Fluorouracil (5-FU)
Drug: BL-8040
Biological: PEGylated recombinant human hyaluronidase (PEGPH20)
Biological: Ramucirumab
Drug: Linagliptin
Drug: Leucovorin
Drug: Cobimetinib
Drug: Paclitaxel
Drug: Cisplatin
Drug: Oxaliplatin
Drug: Tiragolumab
Drug: Atezolizumab

First Posted Date: 2017-09-13

Last Posted Date: 2025-04-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 410

Registration Number: NCT03281369

Locations: 🇦🇺
Blacktown Hospital, Blacktown, New South Wales, Australia
🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
🇮🇱
Rambam Health Care Campus, Haifa, Israel

and more 20 locations